Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips

Kaori Nakamoto, Judith R. Kidd, Robert D. Jenison, Curtis D. Klaassen, Yu-Jui Yvonne Wan, Kenneth K. Kidd, Xiao Bo Zhong

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

OBJECTIVES: Numerous functional polymorphisms in the CYP2C19 gene have been identified; some alleles (e.g. CYP2C19*2 and CYP2C19*3) are associated with poor metabolism of CYP2C19 substrate drugs. Studies have found that the proportion of poor metabolizers, explained by CYP2C19*2 and CYP2C19*3, varies from less than 50% to more than 90% of poor metabolizers. Therefore, phenotype-genotype correlation studies should cover more than CYP2C19*2 and CYP2C19*3. A broader coverage, however, requires an easy-to-use and high-throughput genotyping platform. This broader coverage should also include the recently identified functional allele, CYP2C19*10, which involves a nucleotide change adjacent to the altered nucleotide change in CYP2C19*2. The currently used restriction fragment length polymorphism-based method for genotyping CYP2C19*2 cannot distinguish between CYP2C19*2 and CYP2C19*10. We aim to develop a simple platform that can genotype all CYP2C19 functional alleles. METHODS: We have developed a thin-film biosensor chip platform to genotype 16 exonic CYP2C19 variants, including two sets of two adjacent single nucleotide polymorphisms and 12 single single nucleotide polymorphisms, using a ligation strategy. RESULTS: We demonstrate that this is a rapid, accurate, and inexpensive method for genotyping CYP2C19 variants using individual's genomic DNA samples. We further demonstrate that this genotyping platform can be used to construct a haplotype structure of the CYP2C19 variants in a population, and to assign a haplotype combination to each individual on the basis of his/her genotype results. CONCLUSION: This assay can be applied in pharmacogenomic studies in both basic research and clinical laboratories. It is also an ideal technology for pharmacogenomic tests in both developed and developing countries.

Original languageEnglish (US)
Pages (from-to)103-114
Number of pages12
JournalPharmacogenetics and Genomics
Volume17
Issue number2
DOIs
StatePublished - Feb 2007
Externally publishedYes

Fingerprint

Biosensing Techniques
Alleles
Genotype
Cytochrome P-450 CYP2C19
Haplotypes
Single Nucleotide Polymorphism
Nucleotides
Pharmacogenetics
Developed Countries
Restriction Fragment Length Polymorphisms

Keywords

  • CYP2C19
  • Genotyping
  • Haplotyping
  • Thin-film biosensor chip

ASJC Scopus subject areas

  • Genetics
  • Pharmacology

Cite this

Nakamoto, K., Kidd, J. R., Jenison, R. D., Klaassen, C. D., Wan, Y-J. Y., Kidd, K. K., & Zhong, X. B. (2007). Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips. Pharmacogenetics and Genomics, 17(2), 103-114. https://doi.org/10.1097/FPC.0b013e32801152c2

Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips. / Nakamoto, Kaori; Kidd, Judith R.; Jenison, Robert D.; Klaassen, Curtis D.; Wan, Yu-Jui Yvonne; Kidd, Kenneth K.; Zhong, Xiao Bo.

In: Pharmacogenetics and Genomics, Vol. 17, No. 2, 02.2007, p. 103-114.

Research output: Contribution to journalArticle

Nakamoto, Kaori ; Kidd, Judith R. ; Jenison, Robert D. ; Klaassen, Curtis D. ; Wan, Yu-Jui Yvonne ; Kidd, Kenneth K. ; Zhong, Xiao Bo. / Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips. In: Pharmacogenetics and Genomics. 2007 ; Vol. 17, No. 2. pp. 103-114.
@article{fd8a8110efcd4406b8f4b6153d65e059,
title = "Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips",
abstract = "OBJECTIVES: Numerous functional polymorphisms in the CYP2C19 gene have been identified; some alleles (e.g. CYP2C19*2 and CYP2C19*3) are associated with poor metabolism of CYP2C19 substrate drugs. Studies have found that the proportion of poor metabolizers, explained by CYP2C19*2 and CYP2C19*3, varies from less than 50{\%} to more than 90{\%} of poor metabolizers. Therefore, phenotype-genotype correlation studies should cover more than CYP2C19*2 and CYP2C19*3. A broader coverage, however, requires an easy-to-use and high-throughput genotyping platform. This broader coverage should also include the recently identified functional allele, CYP2C19*10, which involves a nucleotide change adjacent to the altered nucleotide change in CYP2C19*2. The currently used restriction fragment length polymorphism-based method for genotyping CYP2C19*2 cannot distinguish between CYP2C19*2 and CYP2C19*10. We aim to develop a simple platform that can genotype all CYP2C19 functional alleles. METHODS: We have developed a thin-film biosensor chip platform to genotype 16 exonic CYP2C19 variants, including two sets of two adjacent single nucleotide polymorphisms and 12 single single nucleotide polymorphisms, using a ligation strategy. RESULTS: We demonstrate that this is a rapid, accurate, and inexpensive method for genotyping CYP2C19 variants using individual's genomic DNA samples. We further demonstrate that this genotyping platform can be used to construct a haplotype structure of the CYP2C19 variants in a population, and to assign a haplotype combination to each individual on the basis of his/her genotype results. CONCLUSION: This assay can be applied in pharmacogenomic studies in both basic research and clinical laboratories. It is also an ideal technology for pharmacogenomic tests in both developed and developing countries.",
keywords = "CYP2C19, Genotyping, Haplotyping, Thin-film biosensor chip",
author = "Kaori Nakamoto and Kidd, {Judith R.} and Jenison, {Robert D.} and Klaassen, {Curtis D.} and Wan, {Yu-Jui Yvonne} and Kidd, {Kenneth K.} and Zhong, {Xiao Bo}",
year = "2007",
month = "2",
doi = "10.1097/FPC.0b013e32801152c2",
language = "English (US)",
volume = "17",
pages = "103--114",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips

AU - Nakamoto, Kaori

AU - Kidd, Judith R.

AU - Jenison, Robert D.

AU - Klaassen, Curtis D.

AU - Wan, Yu-Jui Yvonne

AU - Kidd, Kenneth K.

AU - Zhong, Xiao Bo

PY - 2007/2

Y1 - 2007/2

N2 - OBJECTIVES: Numerous functional polymorphisms in the CYP2C19 gene have been identified; some alleles (e.g. CYP2C19*2 and CYP2C19*3) are associated with poor metabolism of CYP2C19 substrate drugs. Studies have found that the proportion of poor metabolizers, explained by CYP2C19*2 and CYP2C19*3, varies from less than 50% to more than 90% of poor metabolizers. Therefore, phenotype-genotype correlation studies should cover more than CYP2C19*2 and CYP2C19*3. A broader coverage, however, requires an easy-to-use and high-throughput genotyping platform. This broader coverage should also include the recently identified functional allele, CYP2C19*10, which involves a nucleotide change adjacent to the altered nucleotide change in CYP2C19*2. The currently used restriction fragment length polymorphism-based method for genotyping CYP2C19*2 cannot distinguish between CYP2C19*2 and CYP2C19*10. We aim to develop a simple platform that can genotype all CYP2C19 functional alleles. METHODS: We have developed a thin-film biosensor chip platform to genotype 16 exonic CYP2C19 variants, including two sets of two adjacent single nucleotide polymorphisms and 12 single single nucleotide polymorphisms, using a ligation strategy. RESULTS: We demonstrate that this is a rapid, accurate, and inexpensive method for genotyping CYP2C19 variants using individual's genomic DNA samples. We further demonstrate that this genotyping platform can be used to construct a haplotype structure of the CYP2C19 variants in a population, and to assign a haplotype combination to each individual on the basis of his/her genotype results. CONCLUSION: This assay can be applied in pharmacogenomic studies in both basic research and clinical laboratories. It is also an ideal technology for pharmacogenomic tests in both developed and developing countries.

AB - OBJECTIVES: Numerous functional polymorphisms in the CYP2C19 gene have been identified; some alleles (e.g. CYP2C19*2 and CYP2C19*3) are associated with poor metabolism of CYP2C19 substrate drugs. Studies have found that the proportion of poor metabolizers, explained by CYP2C19*2 and CYP2C19*3, varies from less than 50% to more than 90% of poor metabolizers. Therefore, phenotype-genotype correlation studies should cover more than CYP2C19*2 and CYP2C19*3. A broader coverage, however, requires an easy-to-use and high-throughput genotyping platform. This broader coverage should also include the recently identified functional allele, CYP2C19*10, which involves a nucleotide change adjacent to the altered nucleotide change in CYP2C19*2. The currently used restriction fragment length polymorphism-based method for genotyping CYP2C19*2 cannot distinguish between CYP2C19*2 and CYP2C19*10. We aim to develop a simple platform that can genotype all CYP2C19 functional alleles. METHODS: We have developed a thin-film biosensor chip platform to genotype 16 exonic CYP2C19 variants, including two sets of two adjacent single nucleotide polymorphisms and 12 single single nucleotide polymorphisms, using a ligation strategy. RESULTS: We demonstrate that this is a rapid, accurate, and inexpensive method for genotyping CYP2C19 variants using individual's genomic DNA samples. We further demonstrate that this genotyping platform can be used to construct a haplotype structure of the CYP2C19 variants in a population, and to assign a haplotype combination to each individual on the basis of his/her genotype results. CONCLUSION: This assay can be applied in pharmacogenomic studies in both basic research and clinical laboratories. It is also an ideal technology for pharmacogenomic tests in both developed and developing countries.

KW - CYP2C19

KW - Genotyping

KW - Haplotyping

KW - Thin-film biosensor chip

UR - http://www.scopus.com/inward/record.url?scp=33847062078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847062078&partnerID=8YFLogxK

U2 - 10.1097/FPC.0b013e32801152c2

DO - 10.1097/FPC.0b013e32801152c2

M3 - Article

C2 - 17301690

AN - SCOPUS:33847062078

VL - 17

SP - 103

EP - 114

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 2

ER -